Boston Scientific Corp. (NYSE: BSX) won Food & Drug Administration approval for its Genesys HTA menorrhagia treatment.
The Natick, Mass.-based medical devices giant said the device treats excessive menstrual bleeding by ablating the endometrial lining of the uterus. It’s an upgrade of Boston Scientific’s HTA system featuring a new console, easier set-up, a graphic user interface and “several technology upgrades designed to improve operating performance,” according to a press release.
The Genesys enhancements won CE Mark approval in the European Union in January, according to the release.
The Power of Real World Data to Study Women’s Health at Scale
Veradigm examines key clinical trends, comorbidity profiles, and treatment trends across adolescence, reproductive years, and peri-/post-menopause. Download it today!
Its competition includes a local entry, the NovaSure ablation treatment made by Bedford, Mass.-based Hologic Inc. (NSDQ:HOLX). Hologic touted the 1-millionth NovaSure procedure last summer.
The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.
Top 7 Modern AI-Powered EAP Providers for Global Workforces in 2026
Discover the top AI-powered EAP providers for 2026. Compare platforms like Kyan Health and Spring Health on triage speed, global reach, and clinical quality to transform workforce wellbeing.
This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.